February 23, 2026 09:00 PM GMT US Equity Strategy | North America US Equity Strategy: Institutional 13F Positioning - 4Q25 M | US Equity Strategy North America | Morgan Stanley & Co. LLC | | | --- | --- | --- | | | Equity Strategist | | | | Nick.Lentini@morganstanley.com | | | | Bas.Jaspers@morganstanley.com | | | | Michael J Wilson | | | | Equity Strategist | | | | M.Wilson@morganstanley.com | +1 212 761-2532 | | US investors added to Healthcare and reduced exposure to | Andrew B Pauker | | | | Equity Stra ...

Runway Growth Finance Corp. Overview of Proposed Acquisition of SWK Holdings NASDAQ Listed I RWAY I RWAYL I RWAYZ October 2025 © Runway Growth Capital LLC 2025 Forward-looking Statements This presentation dated October 2025 is being provided by Runway Growth Finance Corp. ("Runway Growth" or the "Company") for discussion purposes only and is neither an offer to sell, nor a solicitation of an offer to purchase, an interest in the Company. It is solely intended to describe the general business, investment obj ...

Group 1 - On September 24, a total of 17 stocks received buy ratings from brokerages, with 4 stocks announcing target prices [1] - Based on the highest target prices, Dongcai Technology, Rongchang Bio, and Changan Automobile ranked highest in target price increase, with expected increases of 51.19%, 32.4%, and 26.54% respectively [1] - Among the stocks receiving buy ratings, the sectors with the most stocks were technology hardware and equipment (3 stocks), pharmaceuticals (2 stocks), biotechnology and life sciences (2 stocks), and food, beverage, and tobacco (2 stocks) [1] Group 2 - 11 stocks maintained their ratings, while 6 stocks received ratings for the first time [1]